Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

All
Media Highlights
Press Releases
Media

Follow the Money

September 28, 2022

Bio-IT World

Read Now
Media

Scribe, Vertex add to gene therapy's advance with $1B+ deal, near-term BLA

September 27, 2022

BioWorld

Read Now
Media

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

September 27, 2022

Scrip

Read Now
Media

Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor

September 27, 2022

BioCentury

Read Now
Media

Natural killers gain more attention with major Franco-US collab

September 27, 2022

The Pharma Letter

Read Now
Media

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

September 27, 2022

Biopharma Dive

Read Now
Press release

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Read Now
Press release

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

July 27, 2026

Read Now
Press release

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

July 23, 2026

Read Now
Press release

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

June 18, 2026

Read Now
Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now
Blog

Publications